Probiotix Health PLC New commercialisation partner in Asia Pacific (3229Z)
2022年9月14日 - 3:02PM
RNSを含む英国規制内ニュース (英語)
TIDMPBX
RNS Number : 3229Z
Probiotix Health PLC
14 September 2022
ProBiotix Health plc
("ProBiotix" or the "Company")
New commercialisation partner in Asia Pacific
ProBiotix Health plc (AQSE: PBX), a life sciences company
developing clinically proven probiotic solutions to tackle chronic
lifestyle diseases like high cholesterol, high blood pressure and
atherosclerosis, announces the appointment of Nutraconnect Pte Ltd
("Nutraconnect") to develop and implement go-to-market strategies
for LP(LDL) (R) as an ingredient, and CholBiome(R) products, in the
Asia Pacific ("APAC") region.
Nutraconnect is a nutraceutical business growth acceleration
service headquartered in Singapore. The company provides end-to-end
solutions for global nutraceutical companies that are looking to
establish a foundation for sustainable growth in the fragmented,
but vibrant APAC market. Nutraconnect possesses an established
network of industry contacts and a wealth of experience in
successfully bringing innovative and science backed ingredients and
products to markets in the region.
Stephen O'Hara, C EO of ProBiotix Health plc, c o mmented :
"Nutraconnect brings extensive industry expertise and a network of
high-level contacts in the APAC region, combined with an extensive
distribution and agency network. This agreement will help expedite
the commercialisation of LP(LDL) (R) and CholBiome (R) in important
countries in the region, whilst allowing ProBiotix to focus
internal resources on developing new opportunities in dairy and
building a presence in the North American market."
For further information, please contact:
ProBiotix Health plc https://probiotixhealth-ir.com/
Stephen O'Hara, Chief Executive Officer Contact via Walbrook below
Peterhouse Capital Ltd (AQSE Corporate Adviser Tel: 020 7220 0500
and Broker)
Mark Anwyl Tel: 020 7469 0930
Duncan Vasey
Walbrook PR Ltd probiotix@walbrookpr.com
Anna Dunphy Mob: 07876 741 001
About ProBiotix - www.probiotixhealth-ir.com
ProBiotix Health was established by OptiBiotix Health Plc to
develop probiotics to tackle cardiovascular disease and other
lifestyle conditions which are affecting growing numbers of people
across the world. Since its creation, ProBiotix has become a global
leader in microbiome modulating probiotics for use in functional
foods, supplements and biotherapeutics.
Independent clinical studies have shown that ProBiotix's
principal product, LP(LDL) (R), which is protected by an extensive
patent portfolio, can reduce key cardiovascular risk biomarkers:
Total Cholesterol of up to 34.6%, LDL-Cholesterol by 28.4%, and
apoB (biomarker of atheroschlerosis) by 28.6% . Since launching its
CholBiome(R) products containing LP(LDL) (R) in May 2017, ProBiotix
has signed over 41 agreements and its products are now
commercialised in 60 countries.
LP(LDL) (R) was designated Generally Recognized As Safe ("GRAS")
by an independent Expert GRAS Panel in the United States in
February 2019, which extends its applications from use as a
supplement to use as a functional ingredient in a wide range of
food, dairy, and beverage products in the USA.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NEXBSGDCBUBDGDX
(END) Dow Jones Newswires
September 14, 2022 02:02 ET (06:02 GMT)
Probiotix Health (AQSE:PBX)
過去 株価チャート
から 9 2024 まで 10 2024
Probiotix Health (AQSE:PBX)
過去 株価チャート
から 10 2023 まで 10 2024